NEXGEL Reports Third Quarter 2025 Financial Results
MWN-AI** Summary
NEXGEL, Inc. (NASDAQ: NXGL), a provider of healthcare, beauty, and OTC products specializing in hydrogel technology, reported its financial results for the third quarter of 2025, demonstrating stability in revenues and improvements in certain operational metrics. For the quarter ending September 30, 2025, NEXGEL recorded a net revenue of $2.93 million, a slight decline from $2.94 million in the same period the previous year. However, this represents an increase from the $2.88 million reported in the second quarter of 2025.
Gross profit reached $1.24 million, up from $1.16 million year-over-year, yielding a gross profit margin of 42.4%, improved from 39.3% in Q3 2024. The company reported a net loss attributable to stockholders of $0.65 million, an improvement from a loss of $0.69 million in Q3 2024. EBITDA for the quarter was ($0.55) million, slightly worse than the previous year's loss of ($0.49) million, indicating ongoing challenges amid stable revenues.
CEO Adam Levy highlighted the company’s focused growth in contract manufacturing and consumer branded products, which are showing promise through strong partnerships and new product launches. NEXGEL’s strategic collaboration with companies like Cintas has boosted its contract manufacturing segment, demonstrating confidence in its advanced hydrogel technology.
As of September 30, 2025, NEXGEL held cash and restricted cash totaling $1.86 million. The company is committed to leveraging its momentum to enhance its operational efficiency and to fuel future growth across its healthcare and beauty brands. Overall, while NEXGEL faces some ongoing losses, it shows signs of operational stability and potential for future growth.
MWN-AI** Analysis
NEXGEL, Inc. (NASDAQ: NXGL) has reported its third-quarter financial results for 2025, showing a slight decline in net revenue alongside a modest improvement in gross profit margin. Despite flat year-over-year revenue at $2.93 million (down 0.20% from Q3 2024), the company has managed to maintain operational efficiencies, evidenced by a gross profit margin increase to 42.4% from 39.3%.
While the net loss narrowed to $0.65 million from $0.69 million in the previous year, ongoing negative EBITDA signals persistent operational challenges. The company's adjusted EBITDA remained stable at a loss of $0.35 million, highlighting that NEXGEL is still navigating its path toward profitability.
The stability in revenue can be attributed to the firm’s contract manufacturing business, particularly strong partnerships which have instilled confidence in its advanced hydrogel technology. Growth in this segment is promising amid the competitive landscape of healthcare and consumer products. For investors, this could signify an opportunity for long-term growth as NEXGEL continues to expand its customer base.
However, there are evident risks. The company holds a cash balance of nearly $938,000 coupled with $920,000 in restricted cash, indicating a potentially tightening liquidity environment. If NEXGEL cannot convert its strategies into consistent revenue growth soon, it may face challenges sustaining operations or scaling production without raising additional capital.
Investors should watch for upcoming product launches and marketing strategies. If these result in increased brand traction, NEXGEL's stock could rebound positively. Caution is advised as current financial health is fragile; therefore, potential buyers should consider a wait-and-see approach, monitoring the outcomes of their strategic initiatives and market reception to new product offerings.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LANGHORNE, Pa., Nov. 11, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its third quarter 2025 financial results for the period ending September 30, 2025.
Third Quarter 2025 Financial Highlights:
- Net Revenue was $2.93 million, compared to $2.94 million in Q3 2024 and $2.88 million in Q2 2025.
- Gross Profit was $1.24 million, compared to $1.16 million in Q3 2024 and $1.26 million in Q2 2025.
- Gross Profit Margin was 42.4%, compared to 39.3% in Q3 2024 and 43.6% in Q2 2025.
- Net loss attributable to NEXGEL stockholders was $0.65 million, compared to $0.69 million in Q3 2024 and $0.67 million in Q2 2025.
- EBITDA 1 , a non-GAAP financial measure, was ($0.55) million, compared to EBITDA of ($0.49) million in Q3 2024 and EBITDA of ($0.53) million in Q2 2025.
- Adjusted EBITDA 1 , a non-GAAP financial measure, was ($0.35) million, compared to Adjusted EBITDA of ($0.35) million in Q3 2024 and Adjusted EBITDA of ($0.42) million in Q2 2025.
“While our revenue was flat year-over-year and sequentially, our Adjusted EBITDA loss continued to narrow sequentially as a result of consistent performance in contract manufacturing and consumer branded products and maintaining discipline in our operational efficiencies,” said Adam Levy, Chief Executive Officer of NEXGEL. “Growth in our contract manufacturing segment, driven by strong partnerships like Cintas, and the successful onboarding of new global customers, continues to demonstrate the market’s confidence in our advanced hydrogel technology. At the same time, our consumer brands are gaining traction with new product launches across beauty and skincare that reflect our innovation and quality. Looking ahead, we remain committed to building on this momentum, driving sustainable growth, and expanding the reach of our innovative products across both our contract manufacturing and consumer brands businesses.”
Third Quarter 2025 Financial Results
For the third quarter of 2025, revenue totaled $2.93 million, a decrease of 0.20%, as compared to $2.94 million for the third quarter of 2024. Contract manufacturing and branded product revenue remained stable year-over-year.
Cost of revenues totaled $1.69 million for the third quarter of 2025, as compared to $1.79 million for the third quarter of 2024. The decrease in cost of revenues is primarily due to a decrease in materials and finished products and a decrease in amortization and depreciation offset by an increase in commission and contract fees and an increase in equipment, production and other expenses.
Gross profit totaled $1.24 million for the third quarter of 2025, as compared to a gross profit of $1.16 million for the third quarter of 2024. Gross profit margin for the third quarter of 2025 was 42.4%, as compared to 39.3% for the third quarter of 2024.
Selling, general and administrative expenses totaled $1.96 million for the third quarter of 2025, as compared to $1.94 million for the third quarter of 2024. The slight increase year-over-year was attributable to increases in compensation and benefits, share-based compensation, and professional and consulting fees offset by a decrease in advertising, marketing and amazon fees.
EBITDA 1 , a non-GAAP financial measure, totaled ($0.55) million for the third quarter of 2025 as compared to ($0.49) million for the third quarter of 2024. Adjusted EBITDA 1 , a non-GAAP financial measure, totaled ($0.35) million for the third quarter of 2025 as compared to ($0.35) million for the third quarter of 2024.
Net loss attributable to NEXGEL stockholders for the third quarter of 2025 was?$0.65 million, as compared to a net loss of $0.69 million for the third quarter of 2024.
As of September 30, 2025, the Company held a cash balance of approximately $938 thousand and a restricted cash balance of $920 thousand related to receiving $1 million in non-dilutive capital from STADA to support upcoming product launches and marketing efforts.
As of November 11, 2025, NEXGEL had 8,143,133 shares of common stock outstanding.
1. EBITDA and Adjusted EBITDA are a non-GAAP measures described in the section titled Non-GAAP Financial Measures” below and reconciled to the most directly comparable GAAP measures at the end of this release.
Third Quarter 2025 Financial Results Conference Call
Date: November 11, 2025
Time: 4:30 p.m. ET
Live Call: 1-800-579-2543 (U.S. Toll Free) or 1-785-424-1789 (International)
Webcast: Events and Presentations
For interested individuals unable to join the conference call, a replay will be available through November 25, 2025, by dialing 1-844-512-2921 (U.S. Toll Free) or 1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 11160116. An archived version of the webcast will also be available for 90 days.
About NEXGEL, INC.
NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include Silverseal ® , Hexagels ® , Turfguard ® , Kenkoderm ® and Silly George ® . Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.
Non-GAAP Financial Measures
Certain Non-GAAP financial measures are included in this press release. In the calculation of these measures, the Company excludes certain items, such as amortization of intangible assets, stock-based compensation, tax impact of adjustments, other unusual items and discrete items impacting income tax expense. The Company believes that excluding such items provides investors and management with a representation of the Company's core operating performance and with information useful in assessing its prospects for the future and underlying trends in the Company's operating expenditures and continuing operations. Management uses such Non-GAAP measures to evaluate financial results and manage operations. The release and the attachments to this release provide a reconciliation of each of the Non-GAAP measures referred to in this release to the most directly comparable GAAP measure. The Non-GAAP financial measures are not meant to be considered a substitute for the corresponding GAAP financial statements and investors should evaluate them carefully. These Non-GAAP financial measures may differ materially from the Non-GAAP financial measures used by other companies.
Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts, including, without limitation, our continuing commitment to building on our momentum, driving sustainable growth, and expanding the reach of our innovative products across both our contract manufacturing and consumer brands businesses.. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2024, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/.
Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
Nexgel@kcsa.com
NEXGEL, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
AS OF SEPTEMBER 30, 2025 AND DECEMBER 31, 2024
(Unaudited)
(in thousands, except share and per share data)
| September 30,2025 | December 31,2024 | |||||||
| ASSETS: | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | 938 | $ | 1,807 | ||||
| Restricted cash | 920 | - | ||||||
| Accounts receivable, net | 839 | 933 | ||||||
| Inventory | 2,019 | 1,751 | ||||||
| Prepaid expenses and other current assets | 886 | 623 | ||||||
| Total current assets | 5,602 | 5,114 | ||||||
| Goodwill | 1,128 | 1,128 | ||||||
| Intangibles, net | 712 | 807 | ||||||
| Property and equipment, net | 1,996 | 2,211 | ||||||
| Operating lease - right of use asset | 2,087 | 1,628 | ||||||
| Other assets | 95 | 95 | ||||||
| Total assets | $ | 11,620 | $ | 10,983 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable | $ | 795 | $ | 761 | ||||
| Accounts payable - related party | 421 | 531 | ||||||
| Accrued expenses and other current liabilities | 530 | 310 | ||||||
| Deferred revenue | 180 | 179 | ||||||
| Current portion of note payable | 99 | 97 | ||||||
| Partnership accrued advance | 920 | - | ||||||
| Warrant liability and contingent consideration liability | 6 | 296 | ||||||
| Financing lease liability, current portion | 64 | 59 | ||||||
| Operating lease liabilities, current portion | 293 | 237 | ||||||
| Total current liabilities | 3,308 | 2,470 | ||||||
| Operating lease liabilities, net of current portion | 1,962 | 1,538 | ||||||
| Financing lease liability, net of current portion | 259 | 307 | ||||||
| Notes payable, net of current portion | 515 | 588 | ||||||
| Total liabilities | 6,044 | 4,903 | ||||||
| Commitments and Contingencies (Note 17) | - | - | ||||||
| Stockholders’ Equity | ||||||||
| Preferred stock, par value $0.001 per share, 5,000,000 shares authorized, no shares issued and outstanding | - | - | ||||||
| Common stock, par value $0.001 per share, 25,000,000 shares authorized; 8,142,766 and 7,638,497 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | 8 | 8 | ||||||
| Additional paid-in capital | 25,204 | 23,743 | ||||||
| Accumulated deficit | (20,026 | ) | (17,996 | ) | ||||
| Total NexGel stockholders’ equity | 5,186 | 5,755 | ||||||
| Non-controlling interest in joint venture | 390 | 325 | ||||||
| Total stockholders’ equity | 5,576 | 6,080 | ||||||
| Total liabilities and stockholders’ equity | $ | 11,620 | $ | 10,983 |
NEXGEL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024
(Unaudited)
(in thousands, except share and per share data)
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenues, net | $ | 2,934 | $ | 2,940 | $ | 8,625 | $ | 5,647 | ||||||||
| Cost of revenues | 1,691 | 1,785 | 4,935 | 3,973 | ||||||||||||
| Gross profit | 1,243 | 1,155 | 3,690 | 1,674 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 7 | - | 8 | 78 | ||||||||||||
| Selling, general and administrative | 1,961 | 1,943 | 5,820 | 4,309 | ||||||||||||
| Total operating expenses | 1,968 | 1,943 | 5,828 | 4,387 | ||||||||||||
| Loss from operations | (725 | ) | (788 | ) | (2,138 | ) | (2,713 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest expense, net | 10 | (20 | ) | (32 | ) | (65 | ) | |||||||||
| Other income | 59 | 44 | 92 | 102 | ||||||||||||
| Changes in fair value of warrant liability | 9 | 10 | 113 | 37 | ||||||||||||
| Total other income (expense), net | 78 | 34 | 173 | 74 | ||||||||||||
| Loss before income taxes | (647 | ) | (754 | ) | (1,965 | ) | (2,639 | ) | ||||||||
| Income tax expense | - | - | - | - | ||||||||||||
| Net loss | (647 | ) | (754 | ) | (1,965 | ) | (2,639 | ) | ||||||||
| Less: Income (loss) attributable to non-controlling interest in joint venture | (6 | ) | 61 | (65 | ) | 208 | ||||||||||
| Net loss attributable to NexGel stockholders | $ | (653 | ) | $ | (693 | ) | $ | (2,030 | ) | $ | (2,431 | ) | ||||
| Net loss per common share - basic | $ | (0.08 | ) | $ | (0.11 | ) | $ | (0.26 | ) | $ | (0.39 | ) | ||||
| Net loss per common share - diluted | $ | (0.08 | ) | $ | (0.11 | ) | $ | (0.26 | ) | $ | (0.39 | ) | ||||
| Weighted average shares used in computing net loss per common share - basic | 7,971,299 | 6,569,403 | 7,757,429 | 6,274,221 | ||||||||||||
| Weighted average shares used in computing net loss per common share – diluted | 7,971,299 | 6,569,403 | 7,757,429 | 6,274,221 |
NEXGEL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024
(Unaudited)
(in thousands)
| Nine Months Ended September 30, | ||||||||
| 2025 | 2024 | |||||||
| Operating Activities | ||||||||
| Net loss | $ | (2,030 | ) | $ | (2,431 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Income (loss) attributable to non-controlling interest in joint venture | 65 | (208 | ) | |||||
| Depreciation and amortization | 338 | 328 | ||||||
| Net changes in operating lease assets and liabilities | 21 | 31 | ||||||
| Share-based compensation | 498 | 271 | ||||||
| Gain on investment in marketable securities | — | (62 | ) | |||||
| Changes in fair value of warrant liability and warrant modification expense | (112 | ) | (37 | ) | ||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable, net | 94 | (261 | ) | |||||
| Inventory | (268 | ) | (459 | ) | ||||
| Prepaid expenses and other assets | (263 | ) | (479 | ) | ||||
| Accounts payable | 34 | 272 | ||||||
| Accounts payable – related party | (110 | ) | — | |||||
| Accrued expenses and other current liabilities | 220 | (132 | ) | |||||
| Deferred revenue | 1 | 159 | ||||||
| Partnership accrued advance | (80 | ) | — | |||||
| Net Cash Used in Operating Activities | (1,592 | ) | (3,008 | ) | ||||
| Investing Activities | ||||||||
| Proceeds from sales of marketable securities | — | 62 | ||||||
| Capital expenditures | (28 | ) | (374 | ) | ||||
| Net cash paid for asset acquisition | — | (400 | ) | |||||
| Net Cash Used in Investing Activities | (28 | ) | (712 | ) | ||||
| Financing Activities | ||||||||
| Proceeds from margin line of credit | — | 345 | ||||||
| Proceeds from STADA (Note 17) | 1,000 | — | ||||||
| Proceeds from equity offerings | 1,055 | 2,135 | ||||||
| Stock issuance costs | (92 | ) | (185 | ) | ||||
| Investment by joint venture partner | — | 37 | ||||||
| Change in contingent consideration liability | — | (164 | ) | |||||
| Payment of contingent consideration liability | (178 | ) | — | |||||
| Principal payment on financing lease liability | (43 | ) | (36 | ) | ||||
| Principal payments of notes payable | (71 | ) | (53 | ) | ||||
| Net Cash Provided by Financing Activities | 1,671 | 2,079 | ||||||
| Net increase (decrease) in cash, cash equivalents and restricted cash | 51 | (1,641 | ) | |||||
| Cash, cash equivalents, and restricted cash, beginning of period | 1,807 | 2,700 | ||||||
| Cash, cash equivalents, and restricted cash, end of period | $ | 1,858 | $ | 1,059 | ||||
| Reconciliation of ending cash, cash equivalents and restricted cash | ||||||||
| Cash and cash equivalents, end of period | $ | 938 | $ | 1,059 | ||||
| Restricted cash, end of period | 920 | — | ||||||
| Total cash, cash equivalents and restricted cash, end of period | $ | 1,858 | $ | 1,059 | ||||
| Supplemental Disclosure of Cash Flow Information | ||||||||
| Cash paid during the year for: | ||||||||
| Interest | $ | 54 | $ | 65 | ||||
| Taxes | $ | — | $ | — | ||||
| Supplemental Non-cash Investing and Financing Activities | ||||||||
| Additional ROU assets and operating lease liabilities from lease modification | $ | 677,267 | $ | - | ||||
| Shares issued in conjunction with asset acquisition | $ | — | $ | 200 | ||||
| Property and equipment financed under notes payable | $ | — | $ | 165 | ||||
| Property and equipment financed under financing leases | $ | — | $ | 416 |
RECONCILIATION OF SELECTED GAAP MEASURES TO NON-GAAP MEASURES
(in thousands, except per share amounts)
CALCULATION OF EBITDA & ADJUSTED EBITDA
| Three Months Ended June 30, | Three Months Ended September 30, | ||||||||||||
| 2025 | 2025 | 2024 | |||||||||||
| Net (loss) income: | $ | (640 | ) | $ | (647 | ) | $ | (754 | ) | ||||
| Less: Loss (income) attributable to non-controlling interest in joint venture | (25 | ) | (6 | ) | 61 | ||||||||
| Net loss attributable to NexGel stockholders | (665 | ) | (653 | ) | (693 | ) | |||||||
| Adjustments: | |||||||||||||
| Depreciation and amortization | 111 | 113 | 184 | ||||||||||
| Interest expense, net | 21 | (10 | ) | 20 | |||||||||
| Income tax expense | - | - | - | ||||||||||
| EBITDA | (533 | ) | (550 | ) | (489 | ) | |||||||
| Change in warrant liability (1) | (13 | ) | (9 | ) | (11 | ) | |||||||
| Share-based compensation expense (2) | 127 | 205 | 153 | ||||||||||
| Adjusted EBITDA: | $ | (419 | ) | $ | (354 | ) | $ | (347 | ) |
| Nine Months Ended September 30, | |||||||||
| 2025 | 2024 | ||||||||
| Net (loss) income: | $ | (1,965 | ) | $ | (2,639 | ) | |||
| Less: Loss (income) attributable to non-controlling interest in joint venture | (65 | ) | 208 | ||||||
| Net loss attributable to NexGel stockholders | (2,030 | ) | (2,431 | ) | |||||
| Adjustments: | |||||||||
| Depreciation and amortization | 338 | 328 | |||||||
| Interest expense, net | 32 | 65 | |||||||
| Income tax expense | - | - | |||||||
| EBITDA | (1,661 | ) | (2,038 | ) | |||||
| Change in warrant liability (1) | (112 | ) | (37 | ) | |||||
| Share-based compensation expense (2) | 498 | 271 | |||||||
| Adjusted EBITDA: | $ | (1,275 | ) | $ | (1,804 | ) |
| (1 | ) | This adjustment gives effect to non-cash warrant liability changes incurred during the periods. | |
| (2 | ) | The adjustments represent share-based compensation expense related to awards of stock options, restricted stock units, or common stock in exchange for services. Although we expect to continue to award stock in exchange for services, the amount of non-cash stock-based compensation is excluded as it is subject to change as a result of one-time or non-recurring projects. No common stock was issued for services in the quarter ended September 30, 2025. |
FAQ**
How does NEXGEL’s recent performance, as reflected in the Q3 2025 financial results, impact investor sentiment towards the company's future, particularly concerning the “NexGel Inc Warrant NXGLW”?
Given the flat revenue growth year-over-year, what strategic initiatives is NEXGEL pursuing to increase profitability, and how do they relate to the “NexGel Inc Warrant NXGLW”?
With the adjusted EBITDA loss remaining consistent, what steps is NEXGEL taking to improve operational efficiencies, and how might this influence the valuation of the “NexGel Inc Warrant NXGLW”?
NEXGEL has indicated a commitment to expanding its consumer brands. What new product launches are planned, and how might these developments affect the trading outlook for investors holding the “NexGel Inc Warrant NXGLW”?
**MWN-AI FAQ is based on asking OpenAI questions about NexGel Inc (NASDAQ: NXGL).
NASDAQ: NXGL
NXGL Trading
18.55% G/L:
$1.14 Last:
72,011 Volume:
$1.0199 Open:
